

**RETRACTION NOTE**

## Retraction Note to: The EQ-5D-5L Valuation Study in Egypt

Sahar A. Al Shabasy<sup>1</sup> · Maggie M. Abbassi<sup>1</sup> · Aureliano Paolo Finch<sup>2</sup> · Darrin Baines<sup>3</sup> · Samar F. Farid<sup>1</sup>

© Springer Nature Switzerland AG 2021

**Retraction to:**

**PharmacoEconomics (2021) 39:549–561**  
<https://doi.org/10.1007/s40273-021-01002-z>

The authors have retracted this article because there is an inconsistency in the preferred model (model 4). This will lead to the worst health state (55555) receiving a higher value than 55455 and will obviously affect the values of other health states as well. All authors agree with this retraction. The authors have been invited to submit a new manuscript using a different model for peer review.

---

The original article can be found online at <https://doi.org/10.1007/s40273-021-01002-z>.

---

✉ Samar F. Farid  
samar.farid@pharma.cu.edu.eg

<sup>1</sup> Department of Clinical Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo 11562, Egypt

<sup>2</sup> EuroQol Group Office, Rotterdam, The Netherlands

<sup>3</sup> Business School, Dorset House Talbot Campus, Bournemouth University, Fern Barrow, Poole, UK